Radioimmunotherapy with Tenarad, a 131I-labelled antibody fragment targeting the extra-domain A1 of tenascin-C, in patients with refractory Hodgkin's lymphoma

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 41, Issue 5, 2014, Pages 867-877

  Aloj, Luigi ^a   D'Ambrosio, Laura ^a   Aurilio, Michela ^a   Morisco, Anna ^a   Frigeri, Ferdinando ^a   Caraco', Corradina ^a   Di Gennaro, Francesca ^a   Capobianco, Gaetana ^a   Giovannoni, Leonardo ^b   Menssen, Hans D ^b   Neri, Dario ^c   Pinto, Antonio ^a   Lastoria, Secondo ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b Philogen SpA   (Italy)

^c ETH ZURICH   (Switzerland)

Author keywords

Dosimetry; Hodgkin's lymphoma; Radioimmunotherapy; Tenascin C

Indexed keywords

BLEOMYCIN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; F16 ANTIBODY SMALL IMMUNOPROTEIN I 131; FLUORODEOXYGLUCOSE; GEMCITABINE; IFOSFAMIDE; LOMUSTINE; METHYLPREDNISOLONE; MITOXANTRONE; NAVELBINE; OXALIPLATIN; PREDNIMUSTINE; PREDNISOLONE; PREDNISONE; PROCARBAZINE; RADIOPHARMACEUTICAL AGENT; TENARAD; UNCLASSIFIED DRUG; VINBLASTINE; VINCRISTINE; IMMUNOGLOBULIN; MONOCLONAL ANTIBODY; RADIOACTIVE IODINE; TENASCIN;

ADULT; ANTIBODY LABELING; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BONE DISEASE; BONE MARROW TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL ARTICLE; COHORT ANALYSIS; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; EXTERNAL BEAM RADIOTHERAPY; FEMALE; HODGKIN DISEASE; HOSPITALIZATION; HUMAN; LEUKOPENIA; LIVER DISEASE; LUNG DISEASE; LYMPHOCYTOPENIA; MALE; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; POSITRON EMISSION TOMOGRAPHY; RADIOIMMUNOTHERAPY; RECURRENT DISEASE; REPEATED DRUG DOSE; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SPLEEN DISEASE; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; CHEMISTRY; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; IMMUNOLOGY; METABOLISM; MULTIMODAL IMAGING; PROCEDURES; PROTEIN TERTIARY STRUCTURE;

ADULT; ANTIBODIES, MONOCLONAL; FEMALE; HODGKIN DISEASE; HUMANS; IMMUNOPROTEINS; IODINE RADIOISOTOPES; MALE; MULTIMODAL IMAGING; POSITRON-EMISSION TOMOGRAPHY; PROTEIN STRUCTURE, TERTIARY; RADIOIMMUNOTHERAPY; RADIOPHARMACEUTICALS; TENASCIN; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84899054761     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-013-2658-6     Document Type: Article

References (39)

1. Bauer K, Skoetz N, Monsef I, Engert A, Brillant C. Comparison of chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for patients with early unfavourable or advanced stage Hodgkin lymphoma. Cochrane Database Syst Rev. 2011:(8):CD007941. doi: 10.1002/14651858.CD007941.pub2
2. Kuruvilla J, Keating A, Crump M. How I treat relapsed and refractory Hodgkin lymphoma. Blood. 2011;117:4208-17.
3. Uhm J, Kuruvilla J. Treatment of newly diagnosed advanced stage Hodgkin lymphoma. Blood Rev. 2012;26:167-74.
4. Brice P. Managing relapsed and refractory Hodgkin lymphoma. Br J Haematol. 2008;141:3-13.
5. Horning S, Fanale M, deVos S, Borchmann P, Illidge T, Engert A, et al. Defining a population of Hodgkin lymphoma patients for novel therapeutics: an international effort [abstract 118]. Ann Oncol. 2008;19 Suppl 4:120-1
6. Younes A. Novel treatment strategies for patients with relapsed classical Hodgkin lymphoma. Hematology Am Soc Hematol Educ Program. 2009:507-19. doi: 10.1182/asheducation-2009.1.507
7. Illidge T, Morschhauser F. Radioimmunotherapy in follicular lymphoma. Best Pract Res Clin Haematol. 2011;24:279-93.
8. Kaminski MS, Tuck M, Estes J, Kolstad A, Ross CW, Zasadny K, et al. 131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med. 2005;352:441-9.
9. Scholz CW, Pinto A, Linkesch W, Linden O, Viardot A, Keller U, et al. (90)Yttrium-ibritumomab-tiuxetan as first-line treatment for follicular lymphoma: 30 months of follow-up data from an international multicenter phase II clinical trial. J Clin Oncol. 2013;31:308-13.
10. Silacci M, Brack S, Schirru G, Marlind J, Ettorre A, Merlo A, et al. Design, construction, and characterization of a large synthetic human antibody phage display library. Proteomics. 2005;5:2340-50.
11. Brack SS, Silacci M, Birchler M, Neri D. Tumor-targeting properties of novel antibodies specific to the large isoform of tenascin-C. Clin Cancer Res. 2006;12:3200-8.
12. Borsi L, Carnemolla B, Nicolo G, Spina B, Tanara G, Zardi L. Expression of different tenascin isoforms in normal, hyperplastic and neoplastic human breast tissues. Int J Cancer. 1992;52:688-92.
13. Berndorff D, Borkowski S, Sieger S, Rother A, Friebe M, Viti F, et al. Radioimmunotherapy of solid tumors by targeting extra domain B fibronectin: identification of the best-suited radioimmunoconjugate. Clin Cancer Res. 2005;11:7053s-63s.
14. Pini A, Viti F, Santucci A, Carnemolla B, Zardi L, Neri P, et al. Design and use of a phage display library. Human antibodies with subnanomolar affinity against a marker of angiogenesis eluted from a two-dimensional gel. J Biol Chem. 1998;273:21769-76.
15. Tijink BM, Neri D, Leemans CR, Budde M, Dinkelborg LM, Stigter-van Walsum M, et al. Radioimmunotherapy of head and neck cancer xenografts using 131I-labeled antibody L19-SIP for selective targeting of tumor vasculature. J Nucl Med. 2006;47:1127-35.
16. Erba PA, Sollini M, Orciuolo E, Traino C, Petrini M, Paganelli G, et al. Radioimmunotherapy with radretumab in patients with relapsed hematologic malignancies. J Nucl Med. 2012;53:922-7.
17. Sauer S, Erba PA, Petrini M, Menrad A, Giovannoni L, Grana C, et al. Expression of the oncofetal ED-B-containing fibronectin isoform in hematologic tumors enables ED-B-targeted 131I-L19SIP radioimmunotherapy in Hodgkin lymphoma patients. Blood. 2009;113:2265-74.
18. Heuveling DA, de Bree R, Vugts DJ, Huisman MC, Giovannoni L, Hoekstra OS, et al. Phase 0 microdosing PET study using the human mini antibody F16SIP in head and neck cancer patients. J Nucl Med. 2013;54:397-401.
19. Aldinucci D, Gloghini A, Pinto A, De Filippi R, Carbone A. The classical Hodgkin's lymphoma microenvironment and its role in promoting tumour growth and immune escape. J Pathol. 2010;221:248-63.
20. Steidl C, Connors JM, Gascoyne RD. Molecular pathogenesis of Hodgkin's lymphoma: increasing evidence of the importance of the microenvironment. J Clin Oncol. 2011;29:1812-26.
21. Oki Y, Younes A. Does rituximab have a place in treating classic Hodgkin lymphoma? Curr Hematol Malig Rep. 2010;5:135-9.
22. Soini Y, Alavaikko M, Lehto VP, Virtanen I. Tenascin in reactive lymph nodes and in malignant lymphomas. Pathol Res Pract. 1992;188:1078-82.
23. Younes A, Oki Y, McLaughlin P, Copeland AR, Goy A, Pro B, et al. Phase 2 study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphoma. Blood. 2012;119:4123-8.
24. Younes A, Romaguera J, Hagemeister F, McLaughlin P, Rodriguez MA, Fiumara P, et al. A pilot study of rituximab in patients with recurrent, classic Hodgkin disease. Cancer. 2003;98:310-4.
25. Khnykin D, Troen G, Berner JM, Delabie J. The expression of fibroblast growth factors and their receptors in Hodgkin's lymphoma. J Pathol. 2006;208:431-8.
26. Wallentine JC, Kim KK, Seiler 3rd CE, Vaughn CP, Crockett DK, Tripp SR, et al. Comprehensive identification of proteins in Hodgkin lymphoma-derived Reed-Sternberg cells by LC-MS/MS. Lab Invest. 2007;87:1113-24.
27. Aloj L, D'Ambrosio L, Aurilio M, Marreno R, Menssen HD, Giovannoni L, et al. Preliminary evaluation of radioimmunotherapy with Tenarad, a I-131 labeled antibody fragment targeting the extra-domain A1 of tenascin-C, in patients with refractory Hodgkin lymphoma. Journal of Clinical Oncology, 2011 ASCO Annual Meeting Abstracts. Vol 29, No. 15 suppl, 8063; 2011.
28. Siegel JA, Thomas SR, Stubbs JB, Stabin MG, Hays MT, Koral KF, et al. MIRD pamphlet no. 16: Techniques for quantitative radiopharmaceutical biodistribution data acquisition and analysis for use in human radiation dose estimates. J Nucl Med. 1999;40:37S-61S.
29. Buijs WC, Siegel JA, Boerman OC, Corstens FH. Absolute organ activity estimated by five different methods of background correction. J Nucl Med. 1998;39:2167-72.
30. Stabin MG, Sparks RB, Crowe E. OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med. 2005;46:1023-7.
31. Sgouros G. Bone marrow dosimetry for radioimmunotherapy: theoretical considerations. J Nucl Med. 1993;34:689-94.
32. Traino AC, Ferrari M, Cremonesi M, Stabin MG. Influence of total-body mass on the scaling of S-factors for patient-specific, blood-based red-marrow dosimetry. Phys Med Biol. 2007;52:5231-48.
33. Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25:579-86.
34. Folkman J. The role of angiogenesis in tumor growth. Semin Cancer Biol. 1992;3:65-71.
35. Birgersdotter A, Baumforth KR, Porwit A, Sjoberg J, Wei W, Bjorkholm M, et al. Inflammation and tissue repair markers distinguish the nodular sclerosis and mixed cellularity subtypes of classical Hodgkin's lymphoma. Br J Cancer. 2009;101:1393-401.
36. Birgersdotter A, Baumforth KR, Wei W, Murray PG, Sjoberg J, Bjorkholm M, et al. Connective tissue growth factor is expressed in malignant cells of Hodgkin lymphoma but not in other mature B-cell lymphomas. Am J Clin Pathol. 2010;133:271-80.
37. Buglio D, Georgakis G, Younes A. Novel small-molecule therapy of Hodgkin lymphoma. Expert Rev Anticancer Ther. 2007;7:735-40.
38. Jona A, Younes A. Novel treatment strategies for patients with relapsed classical Hodgkin lymphoma. Blood Rev. 2010;24:233-8.
39. Kwekkeboom DJ, de Herder WW, Kam BL, van Eijck CH, van Essen M, Kooij PP, et al. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0, Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol. 2008;26:2124-30.